Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

Pasithea Therapeutics (NASDAQ:KTTA) has announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid...

September 26, 2024

Developments

NanoViricides obtains ROFR for all antiviral drug treatments from TheraCour

NanoViricides (NYSE American:NNVC) has announced that it has signed a broad memorandum of understanding agreement granting it the right of first refusal (ROFR) for all antiviral drug developments, including trojan horse...

September 26, 2024

Developments

BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs

BioRestorative Therapies (NASDAQ:BTRX) presented advancements in its metabolic program, ThermoStem, targeting obesity and metabolic disorders, at the 21st Annual International Federation for Adipose Therapeutics and...

September 25, 2024

Developments

Japan’s MHLW approves Aurinia’s LUPKYNIS (voclosporin) for lupus nephritis

Aurinia Pharmaceuticals (NASDAQ:AUPH), has announced that Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved voclosporin, a second-generation calcineurin inhibitor (CNI), in combination with...

September 25, 2024

Developments

Acurx reports CDI antibiotic research results in collaboration with LUMC

Acurx Pharmaceuticals (NASDAQ:ACXP), announced results from its research, in collaboration with Leiden University Medical Center (LUMC), for its lead oral antibiotic candidate, ibezapolstat, to treat patients with C...

September 24, 2024

Developments

Zevra receives FDA approval for Miplyffa to treat NPC

Zevra Therapeutics (NASDAQ:ZVRA), has announced FDA approval for its Miplyffa oral capsules, used in combination with miglustat, for the treatment of Niemann-Pick disease C (NPC) in adult and pediatric patients aged two...

September 23, 2024

Developments

MIEC grants Aethlon full ethics approval for Hemopurifier cancer trial in India

Aethlon Medical (NASDAQ:AEMD), has announced that the Medanta Institutional Ethics Committee (MIEC) has granted full ethics approval for a safety, feasibility, and dose finding study of its Hemopurifier in cancer...

September 19, 2024

Markets

BTIG starts Definitive Healthcare at buy; PT $7

BTIG launched coverage of Definitive Healthcare (NASDAQ:DH) with a “buy” rating and $7 target price. The stock closed at $4.44 on September 16. Definitive Healthcare is one of the industry’s most comprehensive...

September 18, 2024

Developments

Senseonics and Ascensia receive FDA approval for world’s first CGM with 365-day sensor

Senseonics Holdings (NYSE:SENS) and closely-held Ascensia Diabetes Care herald a significant breakthrough in diabetes technology and management, announcing FDA approval of Eversense 365, the world’s first one-year...

September 18, 2024

Developments

PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma

Closely-held PharmaJet has announced a strategic partnership with Scancell Holdings (AIM:SCLP) to supply its Stratis Intramuscular (IM) Needle-free Injection System for delivery of Scancell’s advanced melanoma DNA...

September 17, 2024

Developments

Ripple and AbbVie launch strategic partnership to leverage eye care expertise and drug delivery innovation for next-gen glaucoma therapies

Closely-held Ripple Therapeutics has entered into a collaboration and option-to-lease agreement with AbbeVie (NYSE:ABBV) to develop RTC-620, a next generation, fully biodegradable, sustained-release drug delivery...

September 17, 2024

Developments

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) hosted its second PRO-Talk Live! educational event, by physicians for physicians, in Las Vegas this past weekend. The event featured a prestigious panel of experts, innovators...

September 16, 2024

Subscribe